Jacques Gaudreault - Concepedia

Author

Jacques Gaudreault

Roche (Switzerland)

Also Known As

J GAUDREAULT, J. Gaudreault, JACQUES GAUDREAULT, Jacques Gaudreault

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)Université de Montréal Dynamic Research (United States)University of North Carolina at Chapel Hill Baylor University Medical Center

About

Jacques Gaudreault is an author at Roche (Switzerland) specializing in medicine, immunology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	713
2	Immunology	6	6	370
3	Engineering	1	1	56
4	Biomolecular Engineering	1	1	56
5	Cell Biology	1	1	56

Jacques Gaudreault

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer David H. Johnson, Louis Fehrenbacher, William Novotny, Journal of Clinical Oncology	2004	1.9K
Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration Jacques Gaudreault, David Fei, Jeriza Rusit, Investigative Ophthalmology & Visual Science	2005	501
Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data Kim Margolin, Michael Gordon, Eric Holmgren, Journal of Clinical Oncology	2001	366
Clinical pharmacokinetics of bevacizumab in patients with solid tumors Jianfeng Lü, René Bruno, Steve Eppler, Cancer Chemotherapy and Pharmacology OncologyMedicinePharmacotherapyClinical PharmacokineticsCancer Treatment	2008	343
PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS Jacques Gaudreault, David Fei, Joseph C. Beyer, Retina	2007	185
Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo John R. Lowe, James Araujo, Jihong Yang, Experimental Eye Research InflammationAngiogenesisMedicineVascular PharmacologyImmunology	2007	166
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer David H. Johnson, Louis Fehrenbacher, William Novotny, Journal of Clinical Oncology	2023	116
A Placebo‐Controlled Evaluation of Single, Escalating Doses of CL 284,846, a Non‐Benzodiazepine Hypnotic Bernard Beer, John R. Ieni, Wenhui Wu, The Journal of Clinical Pharmacology	1994	81
Design, Construction, and In Vitro Analyses of Multivalent Antibodies K.F. Miller, Gloria Meng, Jun Liu, The Journal of Immunology EngineeringImmunologyExpress Tandem FabMultivalent AntibodiesImmunotherapy	2003	56
First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin Christophe Schmitt, Markus Abt, Cornelia Ciorciaro, Journal of Cardiovascular Pharmacology	2015	55

Page 1